
About Cornileus Pharmaceuticals
Cornileus Pharmaceuticals is a Healthcare company. Pharmaceutical research, manufacturing, and marketing of pellets and spheres in India with global operations. The company has 14 employees. Its Indian entity Cornileus Pharmaceuticals Private Limited reported revenue of βΉ32.17 Cr. Cornileus Pharmaceuticals offers products and services including Pellets and Sugar or MCC Spheres. Its focus areas include Pharmaceuticals, Manufacturing, Pellets Production and Research and Development.
Company details
Cornileus Pharmaceuticals is engaged in research and development, manufacturing, and marketing of pharmaceutical pellets and related formulations, with facilities located in Visakhapatnam that adhere to cGMP guidelines. Global operations are extended across countries like Mexico, Brazil, and China to deliver healthcare solutions. Quality control measures are implemented to ensure compliance, while continuous product development is pursued to meet market demands. The companys efforts are focused on serving clients through professional approaches in the pharmaceutical sector.
- Employees 14
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website cornileus.com
- Social LinkedIn
- Legal Name Cornileus Pharmaceuticals Pvt Ltd
- Date of Incorporation 28 Dec, 2001
- Jurisdiction Hyderabad, Telangana, India
- Indian entity revenue₹32.17 Cr
FY 2026 · +76% YoY
- Indian entity net profit₹70.4 Lakh
FY 2026 · 2% margin
- Indian entity EBITDA₹4.52 Cr
FY 2026 · 14% margin
- Employee Count14
Associated legal entities of Cornileus Pharmaceuticals
Cornileus Pharmaceuticals operates through Cornileus Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Cornileus Pharmaceuticals Private Limited CIN U24239TG2001PTC038288 | Active | 28 Dec 2001 | Hyderabad, Telangana | ₹32.2 Cr | 124 | 4 | View details |
Products & Services of Cornileus Pharmaceuticals
Cornileus Pharmaceuticals offers a comprehensive portfolio of products and services, including Pellets and Sugar or MCC Spheres.
Research, manufacturing, and marketing of pharmaceutical pellets are carried out by the company for healthcare solutions.
Production and distribution of sugar or MCC spheres are managed by the company as part of its formulation offerings.
Board of directors of Cornileus Pharmaceuticals Private Limited (Cornileus Pharmaceuticals)
Cornileus Pharmaceuticals Private Limited is the primary company behind Cornileus Pharmaceuticals. The board of Cornileus Pharmaceuticals Private Limited currently have 4 directors; the longest-serving is Vijayalakshmi Nalamothu, appointed in 2017. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vijayalakshmi Nalamothu DIN 07964895 | Director | 17 Oct 2017 | 9 yrs 1 mo | Cornileus Pharmaceuticals Private Limited |
| Kiran Kumar Nalamothu DIN 00669908 | Managing Director | 05 Nov 2018 | 8 yrs | Cornileus Pharmaceuticals Private Limited |
| Jagarlamudi Suresh Babu DIN 00141050 | Director | 28 Dec 2020 | 5 yrs 10 mo | Cornileus Pharmaceuticals Private Limited |
| Venkat Samraj Jagarlamudi DIN 07689224 | Director | 28 Dec 2020 | 5 yrs 10 mo | Cornileus Pharmaceuticals Private Limited |
Financials of Cornileus Pharmaceuticals
Figures of Cornileus Pharmaceuticals Private Limited, the primary company behind Cornileus Pharmaceuticals, for FY 2026. Revenue was ₹32.17 Cr (+76% year on year). Net profit was ₹70.4 Lakh (2% margin). EBITDA was ₹4.52 Cr (14% margin). Revenue has grown at a compounded annual rate of -7% over three years and +21% over five years.
- ₹32.17 CrRevenue · FY 2026 · +76% YoY
- ₹70.4 LakhNet profit · 2% margin
- ₹4.52 CrEBITDA · 14% margin
- ₹4.58 CrPaid-up capital
- 124Employees (provident fund records)
- -7%Revenue CAGR, 3 years
- +21%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Cornileus Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Cornileus Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cornileus Pharmaceuticals
Cornileus Pharmaceuticals has 14 employees.
The primary company behind Cornileus Pharmaceuticals, Cornileus Pharmaceuticals Private Limited, reported revenue of βΉ32.17 Cr for FY 2026, up 76% year on year.
Cornileus Pharmaceuticals is engaged in research and development, manufacturing, and marketing of pharmaceutical pellets and related formulations, with facilities located in Visakhapatnam that adhere to cGMP guidelines. Global operations are extended across countries like Mexico, Brazil, and China to deliver healthcare solutions. Quality control measures are implemented to ensure compliance, while continuous product development is pursued to meet market demands. The companys efforts are focused on serving clients through professional approaches in the pharmaceutical sector.
Cornileus Pharmaceuticals offers Pellets and Sugar or MCC Spheres.
Cornileus Pharmaceuticals operates through Cornileus Pharmaceuticals Private Limited.
The legal entities of Cornileus Pharmaceuticals currently have 4 directors, including Jagarlamudi Suresh Babu, Kiran Kumar Nalamothu, Venkat Samraj Jagarlamudi and others.